Iqvia Hldgs Inc Stock Price, News & Analysis

Veeva Systems (NYSE:VEEV) and IQVIA (NYSE:IQV) have announced comprehensive global partnerships in clinical and commercial domains, alongside resolving all pending legal disputes. The long-term agreement enables seamless integration of both companies' software, data, technology, and services.

The commercial partnership establishes master data and third-party access agreements, allowing mutual data usage across platforms including Veeva Network, Veeva Nitro, and Veeva AI. IQVIA has joined multiple Veeva partner programs to support customer integrations. In the clinical domain, IQVIA's participation in Veeva's CRO Clinical Data Partner program will facilitate clinical trials execution using Veeva's software products, particularly in EDC (Electronic Data Capture) implementations.

IQVIA (NYSE:IQV) reported strong Q2 2025 financial results with revenue reaching $4,017 million, up 5.3% year-over-year. The company's Technology & Analytics Solutions (TAS) segment showed robust performance with 8.9% growth to $1,628 million.

Key highlights include GAAP Net Income of $266 million, Adjusted EBITDA of $910 million, and Adjusted Diluted EPS of $2.81. R&D Solutions achieved quarterly bookings of $2.5 billion with a book-to-bill ratio of 1.12x and a contracted backlog of $32.1 billion. The company repurchased $607 million of common stock in Q2.

IQVIA updated its full-year 2025 guidance, projecting revenue between $16,100-16,300 million and Adjusted EBITDA of $3,750-3,825 million.

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, has scheduled its second-quarter 2025 financial results announcement for Tuesday, July 22, 2025, before market opening.

The company will host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. Management will discuss the quarterly results, which will be available on IQVIA's Investor Relations website. Interested participants must register in advance to join the conference call, and a webcast replay will be accessible approximately two hours after the event.

IQVIA (NYSE:IQV) has won the 'Best Mobile App for Patient Engagement' award at the 2025 MedTech Breakthrough Awards for its Health Research Space platform. The platform enables direct-to-patient data collection and engagement for decentralized clinical trials globally through patient-facing mobile apps. Available on web, iOS, and Android, the multilingual platform features robust privacy and security measures while improving trial participant engagement and retention. The solution helps reduce barriers to patient participation in clinical studies by eliminating the need for in-person visits and facilitates long-term follow-up. IQVIA's platform supports real-world decentralized and hybrid studies throughout drug and device development, generating real-world evidence for new medicines and medical innovations. The award recognition came from among 4,500 entries in the MedTech Breakthrough Awards program.

IQVIA (NYSE:IQV) has announced the launch of new AI agents at GTC Paris, developed in collaboration with NVIDIA. These custom-built AI agents leverage NVIDIA's technology including NIM Agent Blueprints, NeMo Customizer, and NeMo Guardrails to enhance workflows and accelerate insights in life sciences. The AI agents will be applied across various use cases including target identification, clinical data review, literature review, market assessment, and HCP engagement. This launch follows IQVIA's strategic collaboration with NVIDIA announced in January, aimed at building custom foundation models and AI workflows to accelerate research, clinical development, and treatment access. The company will showcase more insights at IQVIA TechIQ 2025 conference in London this September.

IQVIA Inc., a subsidiary of IQVIA Holdings Inc. (NYSE:IQV), has priced a $2 billion senior notes offering due 2032. The notes will carry a 6.250% annual interest rate, with semi-annual payments beginning December 1, 2025. The proceeds will primarily be used to repay existing revolving credit facility borrowings and offering-related expenses, with any remaining funds allocated for general corporate purposes. The notes issuance is expected to close around June 4, 2025. The offering is exclusively available to qualified institutional buyers in the US under Rule 144A and non-US investors under Regulation S, as the notes are not registered under the Securities Act.

IQVIA Holdings announced that its subsidiary, IQVIA Inc., plans to raise $2 billion through an offering of senior notes due 2032. The company intends to use the proceeds to repay existing borrowings under its revolving credit facility, cover offering-related fees and expenses, with any remaining funds allocated for general corporate purposes. The Notes will be offered exclusively to qualified institutional buyers in the US under Rule 144A and to non-US investors under Regulation S. The Notes have not been registered under the Securities Act of 1933 and cannot be sold in the US without registration or an applicable exemption.

Rein Therapeutics (NASDAQ: RNTX) has announced the dosing of its first patient in the RENEW Phase 2 trial of LTI-03, targeting idiopathic pulmonary fibrosis (IPF). The trial will evaluate the safety, tolerability, and efficacy of LTI-03, a novel Caveolin-1-related peptide treatment.

The study is designed as a multi-center, randomized, double-blind, placebo-controlled trial that aims to enroll 120 patients across 50 global sites. Participants must have been diagnosed with IPF within 5 years of screening. The trial's primary endpoint focuses on treatment-emergent adverse events through Week 24, while secondary endpoints measure efficacy through FVC, ppFVC, and HRCT metrics. Rein is collaborating with IQVIA for enrollment, and topline interim data is expected in H1 2026.

IQVIA (NYSE:IQV) has announced a strategic collaboration with SCRI Development Innovations, the contract research organization arm of Sarah Cannon Research Institute, to enhance global oncology trials. The partnership combines IQVIA's global reach and expertise in managing one-fifth of U.S. oncology trials with SCRI's community oncology experience and Accelero operational model.

The collaboration aims to streamline clinical trial processes, reduce operational barriers, speed up data delivery, and accelerate the development of new cancer therapies. SCRI's Accelero model facilitates faster trial activation, improved recruitment, and seamless integration of electronic health records with data capture systems for U.S. clinical trials.